Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxy-PEP mucosal penetration study
NCT05853120Phase 4Completed
- Sponsor
- Emory University
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxycycline in sexually transmitted infections (STI) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Emory University. Primary endpoints: Doxycycline Concentrations in Rectal Tissues at Day 2, Doxycycline Concentrations in Vaginal Tissues at Day 2 and 2 more. Started May 2023; status: completed.
02
Drugs
doxycycline
03
Conditions
sexually transmitted infections (STI)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05853120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853120.